Therapeutic Area Expertise

Committed to advancing innovative therapies that make a meaningful difference in patients' lives.

From industry-firsts to well-researched indications, MMS brings a wealth of specialized knowledge across therapeutic areas to ensure that your drug development programs are supported by a team that truly understands the unique challenges and opportunities presented. We are proficient in a diverse range of therapeutic areas, including rare diseases, psychedelics, oncology and radiopharmaceuticals, central nervous system (CNS) disorders, and many others. Our deep understanding of these complex indications, combined with our data-driven approach and cutting-edge technology, allows us to be your trusted partner.

Whether you are pioneering new treatments for rare diseases, exploring the potential of psychedelics, or developing groundbreaking oncology therapies, MMS can bring your program to life through comprehensive solutions that focus on the long-term health of your project.

Review our therapeutic area expertise to understand how MMS can help you achieve your development goals across a variety of indications.

In addition to the pivotal therapeutic areas above, MMS global colleagues possess a depth and breadth of industry expertise that is unmatched in other areas.

Suggested For You

news

November 19th, 2024

MMS Recognized as a Top Workplace by Detroit Free Press and USA Today Network for the Fourth Consecutive Year

perspectives

November 12th, 2024

REMS Logic Modeling: Applying FDA Guidance from November 2024 CDER Webinar

news

November 8th, 2024

MMS Named a Finalist in the 2024 Fierce CRO Awards for Leadership in Regulatory Compliance

perspectives

November 6th, 2024

How to Successfully Manage Rescue Studies and Turn Around Clinical Trials Facing Failure

perspectives

October 29th, 2024

Why Outsourcing QC of Regulatory and Medical Writing Documents is a Competitive Advantage for Large Pharma Companies

perspectives

October 22nd, 2024

Choosing the Right Clinical Trial Design: A Crucial Step in Protocol Development

perspectives

October 15th, 2024

Putting the Action in Diversity Action Plans and the Real-Time Data Visualization Technology Needed to Ensure It Happens

news

October 15th, 2024

MMS Recognized with EcoVadis Bronze Medal for Leadership in ESG Sustainability Efforts as a Leading Clinical Research Organization (CRO)

perspectives

October 8th, 2024

Diversity Action Plan Guidance Part I: Implications for Sponsors

webinar

October 22nd, 2024

Optimal Strategies to Protect Commercially Confidential Information (CCI) in Clinical Documents and Report Trial Results Under Revised EU-CTIS Transparency Rules

perspectives

September 30th, 2024

Meet the Leaders Driving MMS’s European Growth

perspectives

September 30th, 2024

The Future of Data Management and Biostatistics: Trends and Technologies Shaping the Industry